Groundbreaking CRISPR Lab to Accelerate Drug Discovery, Advance Genomic Research

Drug Enforcement Tech

Posted by AI on 2025-08-25 13:52:20 | Last Updated by AI on 2025-08-29 14:29:20

Share: Facebook | Twitter | Whatsapp | Linkedin Visits: 0

---

GlaxoSmithKline (GSK) has established a cutting-edge Laboratory for Genomic Research (LGR) in collaboration with the University of California (UC) Berkeley and UCSF. The LGR will focus on immunology, oncology, and neuroscience, leveraging CRISPR technologies to elucidate the links between genes and disease and speeding up the discovery of novel medicines. The $67 million partnership over five years will bring together GSK's machine learning group, 24 university employees funded by GSK, and up to 14 GSK employees.

The LGR is pioneering in how it combines academic and industrial researchers in a single facility, where they can work together or independently on projects focused on technology, new drug targets, and biological mechanisms. This unified effort will enhance both academic and commercial advancements. The lab will also serve as a resource for researchers at UCSF and Berkeley, providing access to its cutting-edge technology and expertise to answer their own biomedical questions and develop new tools to investigate gene function.

GSK's collaboration with the university builds on its existing relationships with companies like 23andMe, using artificial intelligence and machine learning to correlate genetic variants with disease to expedite the drug development process. The LGR's mission is to deepen our understanding of genetics and discover new targets to create next-generation technologies that will become standard practice in the pharma industry.

Dr. Hal Barron, GSK's chief scientific officer and president of R&D, emphasized the potential of CRISPR technologies to transform drug discovery and advance scientific understanding of gene-disease relationships. This initiative is another example of GSK's commitment to technology innovation to improve patient healthcare. The LGR collaboration is a testament to GSK's dedication to groundbreaking partnerships to drive scientific progress and better patient outcomes.

Go!